Immunoengineering: from molecules
to biomaterials and cell therapies

New York University
- Professor of Chemical and Biomolecular Engineering, Tandon School of Engineering
- Professor of Biology and Chemistry, Faculty of Arts and Sciences
- Professor of Biochemistry and Molecular Pharmacology, NYU Langone Health
- Vice President Bioengineering Strategy

Jeffrey Hubbell is launching an initiative at New York University of build the translational biosciences across New York University, between engineering, the basic sciences, and medicine. Prior to moving to New York, he was at the University of Chicago, helping build Immunoengineering in the Pritzker School of Molecular Engineering. He was previously on the faculty of the Swiss Federal Institute of Technology Lausanne (EPFL, where he served as founding Director of the Institute of Bioengineering and Dean of the School of Life Sciences), the Swiss Federal Institute of Technology Zurich (ETH Zürich) and University of Zurich, the California Institute of Technology, and the University of Texas in Austin. He was elected to the US National Academy of Engineering in 2010, the National Academy of Inventors in 2014, the National Academy of Medicine in 2019, and the American Academy of Arts and Sciences in 2021, and the National Academy of Sciences in 2023. He trained in chemical engineering at Kansas State University (BS) and Rice University (PhD).

With more than 400 papers and 100 issued patents, Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he focuses on biomaterial matrices that mimic the extracellular matrix and on growth factor-extracellular matrix interactions, working in a variety of animal models of regenerative medicine. In immunotherapeutics, he focuses on nanomaterials in vaccines that target lymphoid-resident antigen presenting cells, on protein engineering to modulate the tumor microenvironment and materials engineering to induce anti-tumor immunity, and on protein and materials engineering approaches to deliver antigen to the liver for inverse vaccines to induce tolerance to protein drugs, modulate allergy, and ameliorate autoimmunity.

Personal page: READ MORE >>